Granted Patent
B2
US 12,415,989 · App. 17/039,006 · Granted Sep 16, 2025
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
Inventors:
Bahram Valamehr (San Diego, CA); Ramzey Abujarour (San Diego, CA); Peter Flynn (San Diego, CA)
Assignee:
Fate Therapeutics, Inc.
C12N5/0696C12N5/0081C12N5/0607C12N2501/148C12N2501/415C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/606C12N2501/608C12N2501/727C12N2501/999C12N2502/99C12N2506/1307C12N2533/52C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides cell culture conditions for culturing stem cells, including feeder-free conditions for generating and culturing human induced pluripotent stem cells (iPSCs). More particularly, the invention provides a culture platform that allows long-term culture of pluripotent cells in a feeder-free environment; reprogramming of cells in a feeder-free environment; single-cell dissociation of pluripotent cells; cell sorting of pluripotent cells; maintenance of an undifferentiated status; improved efficiency of reprogramming; and generation of a naïve pluripotent cell.
Claims (14)
1. A method of sorting a population of human cells to obtain a population of cells enriched for pluripotent cells comprising:
a) suspending a mixed population of dissociated cells to thereby produce a suspension comprising the mixed population of cells, wherein the mixed population of cells comprises human induced pluripotent stem cells (hiPSCs) having ground state pluripotency and human non-pluripotent cells; and
b) sorting the cells in the suspension for cells expressing one or both of SSEA4 and TRA181, thereby obtaining an enriched population of cells enriched for the hiPSCs, wherein the hiPSCs of the enriched population of cells comprise the hiPSCs having ground state pluripotency; and
wherein the hiPSCs having ground state pluripotency in the mixed population of cells and the enriched population of cells have the ability to reactivate GATA6, CDX2, and CGB upon differentiation.
2. The method of claim 1 , wherein the suspension comprises at least one of i) a TGFβ inhibitor; ii) a GSK3 inhibitor; iii) a MEK inhibitor, or iv) a Rock inhibitor.
3. The method of claim 1 , wherein sorting is by magnetic beads or flow cytometry.
4. The method of claim 1 , further comprising culturing the enriched population of cells in a culture medium comprising at least one of i) a TGFβ inhibitor; ii) a GSK3 inhibitor; iii) a MEK inhibitor, or iv) a Rock inhibitor, optionally in combination with soluble fibronectin.
5. The method of claim 1 , wherein the sorting comprises sorting the cells in the suspension for cells expressing both of SSEA4 and TRA181.
6. The method of claim 1 , wherein the hiPSCs are produced by contacting non-pluripotent cells with one or more pluripotency factors to induce reprogramming.
7. The method of claim 4 , wherein hiPSCs cultured in the culture medium comprise hiPSCs with ground state pluripotency.
8. The method of claim 4 , wherein the human induced pluripotent stem cells cultured in the culture medium have a higher clonality than human induced pluripotent stem cells not cultured in the culture medium.
9. The method of claim 7 , further comprising culturing the hiPSCs with ground state pluripotency to form colonies having a domed morphology.
10. The method of claim 1 , further comprising preparing the suspension of dissociated cells by culturing an initial cell population comprising the human induced pluripotent stem cells (hiPSCs) in a culture medium, wherein the culturing comprises inhibiting each of TGFβ, GSK3, MEK, and ROCK.
11. The method of claim 1 , wherein the suspension of dissociated cells is feeder-free.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 22, 2021
From: VALAMEHR, BAHRAM; ABUJAROUR, RAMZEY; FLYNN, PETER
To: FATE THERAPEUTICS, INC.
Reel/Frame 056944/0905 →
Continuity (5)
Division
13997014
Provisional Application
61496991
· Jun 14, 2011
Provisional Application
61426369
· Dec 22, 2010
References Cited (400)
US 4797368A
· Carter et al.
· 1989
[cited by applicant]
US 5010175A
· Rutter et al.
· 1991
[cited by applicant]
US 5139941A
· Muzyczka et al.
· 1992
[cited by applicant]
US 5288514A
· Ellman
· 1994
[cited by applicant]
US 5384253A
· Krzyzek et al.
· 1995
[cited by applicant]
US 5478838A
· Arita et al.
· 1995
[cited by applicant]
US 5506337A
· Summerton et al.
· 1996
[cited by applicant]
US 5519134A
· Acevedo et al.
· 1996
[cited by applicant]
US 5525735A
· Gallop et al.
· 1996
[cited by applicant]
US 5539083A
· Cook et al.
· 1996
[cited by applicant]
US 5549974A
· Holmes
· 1996
[cited by applicant]
US 5569588A
· Ashby et al.
· 1996
[cited by applicant]
US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5589466A
· Felgner et al.
· 1996
[cited by applicant]
US 5593853A
· Chen et al.
· 1997
[cited by applicant]
US 5656610A
· Shuler et al.
· 1997
[cited by applicant]
US 5702932A
· Hoy et al.
· 1997
[cited by applicant]
US 5736524A
· Huygen et al.
· 1998
[cited by applicant]
US 5780448A
· Davis
· 1998
[cited by applicant]
US 5789215A
· Berns et al.
· 1998
[cited by applicant]
US 5824837A
· Chen et al.
· 1998
[cited by applicant]
US 5843780A
· Thomson
· 1998
[cited by applicant]
US 5945100A
· Fick
· 1999
[cited by applicant]
US 5981274A
· Tyrrell et al.
· 1999
[cited by applicant]
US 5994136A
· Naldini et al.
· 1999
[cited by applicant]
US 5994624A
· Trolinder et al.
· 1999
[cited by applicant]
US 6013516A
· Verma et al.
· 2000
[cited by applicant]
US 6030943A
· Crumb et al.
· 2000
[cited by applicant]
US 6200806B1
· Thomson
· 2001
[cited by applicant]
US 6534476B2
· Miyazono et al.
· 2003
[cited by applicant]
US 6692736B2
· Yu et al.
· 2004
[cited by applicant]
US 6696440B1
· Bridges et al.
· 2004
[cited by applicant]
US 6703420B1
· Hobbs, Jr.
· 2004
[cited by applicant]
US 6730293B1
· Rothbard et al.
· 2004
[cited by applicant]
US 6875608B1
· Smith et al.
· 2005
[cited by applicant]
US 7029913B2
· Thomson
· 2006
[cited by applicant]
US 7265138B2
· Doherty et al.
· 2007
[cited by applicant]
US 7585844B2
· Turner et al.
· 2009
[cited by applicant]
US 8044201B2
· Xu et al.
· 2011
[cited by applicant]
US 8222034B2
· Amit
· 2012
[cited by examiner]
US 8298825B1
· Hochedlinger et al.
· 2012
[cited by applicant]
US 8524498B2
· Geijsen et al.
· 2013
[cited by applicant]
US 8603818B1
· Hochedlinger et al.
· 2013
[cited by applicant]
US 8906677B2
· Li et al.
· 2014
[cited by applicant]
US 9005968B2
· Lin et al.
· 2015
[cited by applicant]
US 9068170B2
· Zhou et al.
· 2015
[cited by applicant]
US 9166832B1
· Li et al.
· 2015
[cited by applicant]
US 9295697B2
· Yu
· 2016
[cited by applicant]
US 9394524B2
· Shi et al.
· 2016
[cited by applicant]
US 9534205B2
· Shi et al.
· 2017
[cited by applicant]
US 9540615B2
· Shi et al.
· 2017
[cited by applicant]
US 9732319B2
· Valamehr et al.
· 2017
[cited by applicant]
US 20020142457A1
· Umezawa et al.
· 2002
[cited by applicant]
US 20030087919A1
· Nagarathnam et al.
· 2003
[cited by applicant]
US 20030125344A1
· Nagarathnam et al.
· 2003
[cited by applicant]
US 20030204862A1
· Kuehn et al.
· 2003
[cited by applicant]
US 20040014755A1
· Nagarathnam et al.
· 2004
[cited by applicant]
US 20040157324A1
· Spradling et al.
· 2004
[cited by applicant]
US 20050075276A1
· Rudd
· 2005
[cited by applicant]
US 20050130144A1
· Nakatsuji et al.
· 2005
[cited by applicant]
US 20050192304A1
· Nagarathnam et al.
· 2005
[cited by applicant]
US 20050209261A1
· Nagarathnam et al.
· 2005
[cited by applicant]
US 20060182724A1
· Riordan
· 2006
[cited by applicant]
US 20070128719A1
· Tseng et al.
· 2007
[cited by applicant]
US 20070141703A1
· Xu et al.
· 2007
[cited by applicant]
US 20070161107A1
· Mummery et al.
· 2007
[cited by applicant]
US 20070259423A1
· Odorico et al.
· 2007
[cited by applicant]
US 20070264709A1
· Smith et al.
· 2007
[cited by applicant]
US 20070269412A1
· Kopyov
· 2007
[cited by applicant]
US 20070298496A1
· Kuo
· 2007
[cited by examiner]
US 20080242594A1
· McKay et al.
· 2008
[cited by applicant]
US 20080268533A1
· Dalton et al.
· 2008
[cited by applicant]
US 20090227032A1
· Yamanaka et al.
· 2009
[cited by applicant]
US 20090304646A1
· Sakurada et al.
· 2009
[cited by applicant]
US 20100009442A1
· Sasai et al.
· 2010
[cited by applicant]
US 20100093090A1
· Deng et al.
· 2010
[cited by applicant]
US 20100150889A1
· Townes et al.
· 2010
[cited by applicant]
US 20100303775A1
· Raya
· 2010
[cited by applicant]
US 20110033931A1
· Schwartz et al.
· 2011
[cited by applicant]
US 20110039332A1
· Sakurada et al.
· 2011
[cited by applicant]
US 20110306516A1
· Kahler et al.
· 2011
[cited by applicant]
US 20120122212A1
· Grskovic et al.
· 2012
[cited by applicant]
US 20120128655A1
· Kim et al.
· 2012
[cited by applicant]
US 20130011918A1
· West et al.
· 2013
[cited by applicant]
CN 101356270A
· 2009
[cited by applicant]
CN 101563449A
· 2009
[cited by applicant]
CN 102597221A
· 2012
[cited by applicant]
EP 1970446A1
· 2008
[cited by applicant]
EP 1992360A1
· 2008
[cited by applicant]
EP 3371314A1
· 2018
[cited by applicant]
GB 2436737A
· 2007
[cited by applicant]
GB 2450603A
· 2008
[cited by applicant]
JP 2007508026A
· 2007
[cited by applicant]
JP 2008099662A
· 2008
[cited by applicant]
JP 2008307007A
· 2008
[cited by applicant]
JP 2010504090A
· 2010
[cited by applicant]
JP 2010529851A
· 2010
[cited by applicant]
JP 2012510526A
· 2012
[cited by applicant]
JP 2013507932A
· 2013
[cited by applicant]
JP 2013509864A
· 2013
[cited by applicant]
JP 2013510567A
· 2013
[cited by applicant]
WO WO1991019735A1
· 1991
[cited by applicant]
WO WO1992000091A1
· 1992
[cited by applicant]
WO WO1993020242A1
· 1993
[cited by applicant]
WO WO1997000271A1
· 1997
[cited by applicant]
WO WO1998006433A1
· 1998
[cited by applicant]
WO WO1999001426A1
· 1999
[cited by applicant]
WO WO2000078351A1
· 2000
[cited by applicant]
WO WO2001017562A1
· 2001
[cited by applicant]
WO WO2002006213A2
· 2002
[cited by applicant]
WO WO2002076976A2
· 2002
[cited by applicant]
WO WO2002076977A2
· 2002
[cited by applicant]
WO WO2002088346A2
· 2002
[cited by applicant]
WO WO2003059913A1
· 2003
[cited by applicant]
WO WO2003062225A1
· 2003
[cited by applicant]
WO WO2003062227A1
· 2003
[cited by applicant]
WO WO2003077914A1
· 2003
[cited by applicant]
WO WO2003082808A1
· 2003
[cited by applicant]
WO WO2003095628A2
· 2003
[cited by applicant]
WO WO2004039796A1
· 2004
[cited by applicant]
WO WO2004045617A1
· 2004
[cited by applicant]
WO WO2005035506A1
· 2005
[cited by applicant]
WO WO2005038010A2
· 2005
[cited by applicant]
WO WO2005051301A2
· 2005
[cited by applicant]
WO WO2005074643A2
· 2005
[cited by applicant]
WO WO2005084158A2
· 2005
[cited by applicant]
WO WO2007016566A2
· 2007
[cited by applicant]
WO WO2007044084A2
· 2007
[cited by applicant]
WO WO2007069666A1
· 2007
[cited by applicant]
WO WO2007085827A2
· 2007
[cited by applicant]
WO WO2007113505A2
· 2007
[cited by applicant]
WO WO2007123667A2
· 2007
[cited by applicant]
WO WO2008006583A1
· 2008
[cited by applicant]
WO WO2008011093A2
· 2008
[cited by applicant]
WO WO2008015418A2
· 2008
[cited by applicant]
WO WO2008035110A1
· 2008
[cited by applicant]
WO WO2008056173A2
· 2008
[cited by applicant]
WO WO2008088882A2
· 2008
[cited by applicant]
WO WO2008089351A1
· 2008
[cited by applicant]
WO WO2008094597A2
· 2008
[cited by applicant]
WO WO2008105630A1
· 2008
[cited by applicant]
WO WO2008108741A1
· 2008
[cited by applicant]
WO WO2008126932A2
· 2008
[cited by applicant]
WO WO2008129554A1
· 2008
[cited by applicant]
WO WO2009006422A1
· 2009
[cited by applicant]
WO WO2009007851A2
· 2009
[cited by applicant]
WO WO2009007852A2
· 2009
[cited by applicant]
WO WO2009032194A1
· 2009
[cited by applicant]
WO WO2009032456A2
· 2009
[cited by applicant]
WO WO2009057831A1
· 2009
[cited by applicant]
WO WO2009061442A1
· 2009
[cited by applicant]
WO WO2009067756A1
· 2009
[cited by applicant]
WO WO2009067757A1
· 2009
[cited by applicant]
WO WO2009073523A2
· 2009
[cited by applicant]
WO WO2009115295A1
· 2009
[cited by applicant]
WO WO2009117439A1
· 2009
[cited by applicant]
WO WO2009117439A2
· 2009
[cited by examiner]
WO WO2010019569A1
· 2010
[cited by examiner]
WO WO2010053472A1
· 2010
[cited by applicant]
WO WO2010065721A1
· 2010
[cited by applicant]
WO WO2010077955A1
· 2010
[cited by applicant]
WO WO2010120785A2
· 2010
[cited by applicant]
WO WO2011047300A1
· 2011
[cited by applicant]
WO WO2011056971A2
· 2011
[cited by applicant]
WO WO2011058558A2
· 2011
[cited by applicant]
WO WO2011058558A3
· 2011
[cited by applicant]
WO WO2011090221A1
· 2011
[cited by applicant]
WO WO2011109695A1
· 2011
[cited by applicant]
WO WO2011158852A1
· 2011
[cited by applicant]
WO WO2011159692A1
· 2011
[cited by applicant]
WO WO2012087965A2
· 2012
[cited by applicant]
WO WO2013070852A2
· 2013
[cited by applicant]
WO WO2013159103A1
· 2013
[cited by applicant]
WO WO2013176197A1
· 2013
[cited by applicant]
WO WO2015134652A1
· 2015
[cited by applicant]
WO WO2017066634A1
· 2017
[cited by applicant]
Zhou and Ding (Current Opinions in Hematology. Jul. 2010. 17:276-280 (Year: 2010).
[cited by examiner]
Takashima et al. Cell 158:1254-1269, 2014 (Year: 2014).
[cited by examiner]
Aasen et al., “Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes”, Nature Biotechnology, 26:1276-1284 (2008).
[cited by applicant]
Abujarour, R. et al. (2013, e-published Jan. 31, 2013). “Optimized surface markers for the prospective isolation of high-quality hiPSCs using flow cytometry selection,” Sci Rep 3:1179.
[cited by applicant]
Adcock, “HDAC inhibitors as anti-inflammatory agents”, British Journal of Pharmacology, 150(7):829-831 (2007).
[cited by applicant]
Adhikary and Eilers, “Transcriptional regulation and transformation by Myc proteins”, Nat Rev Mol Cell Biol., 6(8): 635-645 (2005).
[cited by applicant]
Alessi et al., “Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Ba”, Current Biology, 7(4): 261-269 (1997).
[cited by applicant]
Amit et al., “Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture,” Developmental Biology, 227:271-278 (2000).
[cited by applicant]
Aoi et al., “Generation of Pluripotent Stem Cells from Adult Mouse Liver and Stomach Cells,” Science Express, Feb. 2008 (Corrected Aug. 2008), DO1 10.1126/science.1154884, 8 pages.
[cited by applicant]
Artyomov et al., “A model for genetic and epigenetic regulatory networks identifies rare pathways for transcription factor induced pluripotency”, PLoS Computational Biology, 6(5):e1000785, 1-14 (2010).
[cited by applicant]
Barrett et al., “The discovery of the benzhydromate MEK inhibitors CI-1040 and PD 0325901,” Bioorganic & Medicinal Chemistry Letters, 18(24):6501-6504 (2008).
[cited by applicant]
Beaujean et al., “Induction of early transcription in one-cell mouse embryos by microinjection of the nonhistone chromosomal protein HMG-I”, Developmental Biology, 221(2): 337-354 (2000).
[cited by applicant]
Bedel et al., “Preventing pluripotent cell teratoma in regenerative medicine applied to hematology disorders,” Stem Cells Translational Medicine, 6:382-393 (2017).
[cited by applicant]
Bertrand, “Structural Characterization of the GSK-313 Active Site Using Selective and Non-selective ATP-mimetic Inhibitors”, Journal of Molecular Biology, 333(2): 393-407 (2003).
[cited by applicant]
Blelloch et al., “Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus”, Stem Cells, 24(9): 2007-2013 (2006).
[cited by applicant]
Blomer et al., “Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector”, Journal of Virology, 71(9):6641-6649 (1997).
[cited by applicant]
Brambrink et al., “Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells”, Cell Stem Cell, 2(2): 151-159 (2008).
[cited by applicant]
Brevini et al., “Embryonic stem cells in domestic animals. No shortcuts to pig embryonic stem cells,” Theriogenology, 74:544-550 (2010).
[cited by applicant]
Brons et al., “Derivation of pluripotent epiblast stem cells from mammalian embryos”, Nature, 448: 191-195 (2007).
[cited by applicant]
Bru et al., “Rapid induction of pluripotency genes after exposure of human somatic cells to mouse ES cell extracts,” Exp. Cell Res., 314:2634-2642 (2008).
[cited by applicant]
Brueckner, et al., “Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases”, Cancer Research, 65(14): 6305-6311 (2005).
[cited by applicant]
Buta et al., “Reconsidering pluripotency tests: do we still need teratoma assays?,” Stem Cell Research, 11:552-562 (2013).
[cited by applicant]
Byfield et al., “SB-505124 is a selective inhibitor of transforming growth factor-0 type I receptors ALK4, Alks, and ALK7”, Molecular Pharmacology, 65(3):744-752 (2004).
[cited by applicant]
Callahan et al., “Identification of novel inhibitors of the transforming growth factor 131 (TGF-(31) Type 1 receptor (ALKS)”, J. Med Chem., 45(5): 999-1001 (2002). (Abstract).
[cited by applicant]
Chahine et al., Modulation of L-type Ca2+ channels in neonatal rat heart by a novel Ca2+ channel agonise, Canadian Journal of Physiology and Pharmacology, 81(2): 135-141 (2003).
[cited by applicant]
Chambers et al., “Nanog safeguards pluripotency and mediates germline development”, Nature, 450: 1230-1234 (2007).
[cited by applicant]
Chang et al., “Transforming growth factor-beta signaling in breast cancer”, Frontiers in Bioscience, 12: 4393-4401 (2007).
[cited by applicant]
Chen and Okayama, “High-efficiency transformation of mammalian cells by plasmid DNA”, Molecular and Cellular Biology, 7(8): 2745-2752 (1987).
[cited by applicant]
Chen et al., ““Analogous” Organic Synthesis of Small-Compound Libraries: Validation of Combinatorial Chemistry in Small-Molecule Synthesis”, J. Amer. Chem. Soc., 116(6): 26612662 (1994).
[cited by applicant]
Chen et al., “Reversine increases the plasticity of lineage-committed mammalian cells”, PNAS, 104(25): 10482-10487 (2007).
[cited by applicant]
Chen et al., “Self-renewal of embryonic stem cells by a small molecule,” PNAS, 103(46): 17266-17271 (2006).
[cited by applicant]
Chin et al., “Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures,” Cell Stem Cell 5, Jul. 2009, pp. 111-123.
[cited by applicant]
Chin et al., “Inhibition of GSK30 is a common event in neuroprotection by different survival factors”, Molecular Brain Research, 137(1-2):193-201 (2005).
[cited by applicant]
Chin et al., “Molecular analyses of human induced pluripotent stem cells and embryonic stem cells,” Cell Stem Cell 7, Aug. 2010, pp. 263-269.
[cited by applicant]
Cho et al., “An unnatural biopolymer”, Science, 261(5126): 1303-1305 (1993).
[cited by applicant]
Chou et al., “The growth factor environment defines distinct pluripotent ground states in novel blastocyst-derived stem cells”, Cell, 135(3): 449-461 (2008).
[cited by applicant]
Chow, et al., “Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors”, Cytometry (Communicati…
[cited by applicant]
Christen et al., “Regeneration and reprogramming compared”, BMC Biol, 8: 5, 14 pages (2010).
[cited by applicant]
Claassen et al., “ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells”, Molecular Reproduction and Development, 76(8): 722-732 (2009).
[cited by applicant]
Collas et al., “On the way to reprogramming cells to pluripotency using cell-free extracts”, Reproductive BioMedicine Online, 12(6): 762-770 (2006).
[cited by applicant]
Colman and Dreesen, “Induced pluripotent stem cells and the stability of the differentiated state”, EMBO Reports,10(7): 714-721 (2009).
[cited by applicant]
Condorelli, G. et al., “Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: Implications for myocardium regeneration,” PNAS, 98(19): 10733-10738 (2001).
[cited by applicant]
Conti et al., “Niche-independent symmetrical self-renewal of a mammalian tissue stem cell”, PLoS Biol., 3(9): e283, 1594-1606 (2005).
[cited by applicant]
Cotten et al., “High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles”, PNAS, 89(13…
[cited by applicant]
Cui et al., “Selective inhibition of TGF-r3 responsive genes by Smad-interacting peptide aptamers from FoxH1, Lefl and CBP”, Oncogene, 24: 3864-3874 (2005).
[cited by applicant]
D'Amour et al., “Efficient differentiation of human embryonic stem cells to definitive endoderm”, Nat Biotechnol, 23(12): 1534-1541 (2005).
[cited by applicant]
Daheron, L. et al. (Jun. 10, 2012). “Blood—SeV derived fibroblast generated iPSCs,” StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute 7:48, 7 pages.
[cited by applicant]
Dang et al., “The biology of the mammalian Kruppel-like family of transcription factors”, The International Journal of Biochemistry & Cell Biology, 32(11-12): 1103-1121 (2000).
[cited by applicant]
Darenfed, et al., “Molecular characterization of the effects of Y-27632”, Cell Motil Cytoskeleton, 64(2): 97-109 (2007).
[cited by applicant]
De Felipe, “Polycistronic viral vectors,” Curr. Gene Ther., 2:355-378 (2002).
[cited by applicant]
Declercq et al., “Zic3 enhances the generation of mouse induced pluripotent stem cells,” Stem Cells Development, 22(14):2017-2026 (2013).
[cited by applicant]
De Gouville and Huet, “Inhibition of ALKS as a new approach to treat liver fibrotic diseases”, Drug News Perspective, 19(2): 85-90 (2006).
[cited by applicant]
Debs et al., “Regulation of gene expression in vivo by liposome-mediated delivery of a purified transcription factor”, The Journal of Biological Chemistry, 265: 10189-10192 (1990).
[cited by applicant]
Demers et al., “Rat embryonic stem-like (ES-like) cells can contribute to extraembryonic tissues in vivo”, Cloning Stem Cells, 9(4): 512-522 (2007).
[cited by applicant]
Dimos et al., “Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons”, Science, 321(5893): 1218-1221 (2008).
[cited by applicant]
Djuric and Ellis, “Epigenetics of induced pluripotency, the seven-headed dragon”, Stem Cell Research and Therapy, 1(1):3, 7 pages (2010).
[cited by applicant]
Do and Scholer, “Nuclei of embryonic stem cells reprogram somatic cells”, Stem Cells, 22(6): 941-949 (2004).
[cited by applicant]
Do, J. T. et al., “Erasure of cellular memory by fusion with pluripotent cells”, Stem Cells, 25(4): 1013-1020 (2007).
[cited by applicant]
Dravida, S. et al., “The transdifferentiation potential of limbal fibroblast-like cells,” Developmental Brain Research, 160(2): 239-251 (2005).
[cited by applicant]
Dvorak et al., “Expression and potential role of fibroblast growth factor 2 and its receptors in human embryonic stem cells”, Stem Cells, 23(8): 1200-1211 (2005).
[cited by applicant]
Efe, Jem E. et al., “Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy,” Nature Cell Biology, 13(3): 215-222 (2011).
[cited by applicant]
Egler et al., “Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death”, Clin. Cancer Res., 14(10): 3132-3140 (2008).
[cited by applicant]
Elliott and O'Hare, “Intercellular trafficking and protein delivery by a herpesvirus structural protein”, Cell, 88(2): 223-233 (1997).
[cited by applicant]
Emre et al., “The ROCK inhibitor Y-27632 improves recovery of human embryonic stem cells after fluorescence-activated cell sorting with multiple cell surface markers”, PLoS One, 5(8): e12148 (2010).
[cited by applicant]
Engel et al., “Allosteric activation of the protein kinase PDKI with low molecular weight compounds”, The EMBO Journal, 25(23): 5469-5480 (2006).
[cited by applicant]
English and Cobb, “Pharmacological inhibitors of MAPK pathways”, Trends in Pharmaceutical Sciences, 23(1): 40-45 (2002).
[cited by applicant]
EP Application No. 09721278.1, Extended European Search Report dated Jun. 1, 2011, 11 pages.
[cited by applicant]
EP Application No. 10824189.4, Extended European Search Report dated May 29, 2013, 8 pages.
[cited by applicant]
EP Application No. 11852133.5, Extended European Search Report dated Aug. 13, 2014, 7 pages.
[cited by applicant]
EP Application No. 15177122.7, Extended European Search Report dated Oct. 27, 2015.
[cited by applicant]
Epsztejn-Litman, et al., “De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes”, Nature Structural & Molecular Biology, 15(11): 1176-1183, 9 pages (2008).
[cited by applicant]
Ernst et al., “gp130-mediated Signal Transduction in Embryonic Stem Cells Involves Activation of Jak and Ras/Mitogen-activated Protein Kinase Pathways”, J. Biol. Chem., 271(47): 30163-30143 (1996).
[cited by applicant]
Esteban et al., “Vitamin C enhances the generation of mouse and human induced pluripotent stem cells”, Cell Stem Cell, 6(1): 71-79 (2010). Epub Dec. 31, 2009.
[cited by applicant]
Fang et al., “Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines”, Cancer Research, 63: 75637570 (2003).
[cited by applicant]
Feldman et al., “G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis”, Nature Cell Biology, 8(2): 188-194 (2006).
[cited by applicant]
Feng et al., “Molecules that Promote or Enhance Reprogramming of Somatic Cells to Induced pluripotent stem cells”, Cell Stem Cell, 4(4):301-312 (2009).
[cited by applicant]
Fernandes et al., “A dermal niche for multipotent adult skin-derived precursor cells”, Nature Cell Biology, 6: 1082-1093 (2004).
[cited by applicant]
Frame and Cohen, “GSK3 takes centre stage more than 20 years after its discovery”, Biochemical Journal, 359(Pt 1): 1-16 (2001).
[cited by applicant]
Frankel and Pabo, “Cellular uptake of the tat protein from human immunodeficiency virus”, Cell, 55(6): 1289-1193 (1988).
[cited by applicant]
Franzen et al., “Cloning of a TGFI3 type I receptor that forms a heteromeric complex with the TGFI3 type II receptor”, Cell, 75(4): 681-692 (1993).
[cited by applicant]
Furumai et al., “Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin”, PNAS, 98(1): 87-92 (2001).
[cited by applicant]
Gellibert et al., “Discovery of 4-{443-(Pyridin-2-y1)-1H-pyrazol-4-yllpyridin-2-yll-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor-13 Type I Receptor …
[cited by applicant]
Gomez et al., “Derivation of cat embryonic stem-like cells from in vitro-produced blastocysts on homologous and heterologous feeder cells,” Theriogenology, 74:498-515 (2010).
[cited by applicant]
Gonzalez et al., “Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector”, PNAS, 106(22): 8918-8922 (2009).
[cited by applicant]
Gonzalez, F. et al. (Apr. 2011, e-published Feb. 22, 2011). “Methods for making induced pluripotent stem cells: reprogramming a la carte,” Nat Rev Genet 12(4):231-242.
[cited by applicant]
Gopal, “Gene transfer method for transient gene expression, stable transformation, and cotransformation of suspension cell cultures”, Molecular and Cellular Biology, 5(5):11881190 (1985).
[cited by applicant]
Gore, “Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies”, Nature Clinical Practice Oncology, 2(Suppl 1): S30-S35 (2005).
[cited by applicant]
Gore, et al., “Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms”, Cancer Research, 66(12): 6361-6369 (2006).
[cited by applicant]
Gould et al., “Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice”, Pharmacological Research, 48(1): 49-53 (2003).
[cited by applicant]
Gould, et al., “AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test”, The International Journal of Neuropsychopharmacology, 7(4): 387-390 (2004).
[cited by applicant]
Graf and Enver, “Forcing cells to change lineages”, Nature, 462(7273): 587-594 (2009).
[cited by applicant]
Graham and Van Der Eb, “A new technique for the assay of infectivity of human adenovirus 5 DNA”, Virology, 52(2): 456-467 (1973).
[cited by applicant]
Green and Lowenstein, “Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein”, Cell, 55(6): 1179-1188 (1988).
[cited by applicant]
Grunhaus et al., “Association of vaccinia virus-expressed adenovirus E3-19K glycoprotein with class I MHC and its effects on virulence in a murine pneumonia model”, Seminar in Virology, 200(2):535-546 (1992).
[cited by applicant]
Gump et al., “TAT transduction: the molecular mechanism and therapeutic prospects”, (2007) Trends Mol Med. Oct;13(10):443-8 (2007).
[cited by applicant]
Guo et al., “Klf4 reverts developmentally programmed restriction of ground state pluripotency”, Development, 136: 1063-1069 (2009).
[cited by applicant]
Hakelien et al., “Transient alteration of cell fate using a nuclear and cytoplasmic extract of an insulinoma cell line,” BBRC, 316: 834-841 (2004).
[cited by applicant]
Han and Sidhu, “Current concepts in reprogramming somatic cells to pluripotent state”, Curr Stem Cell Res Ther, 3: 66-74 (2008).
[cited by applicant]
Han and Yoon, “Induced pluripotent stem cells: emerging techniques for nuclear reprogramming”, Antioxidants & Redox Signaling, 15(7): 1799-1820 92011).
[cited by applicant]
Han et al., “Direct reprogramming of fibroblasts into epiblast stem cells”, Nat Cell Biol, 13(1): 66-71 (2011).
[cited by applicant]
Han et al., “HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region”, Immunology Letters, 108(2):143-150 (2007).
[cited by applicant]
Hanna et al., “Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin,” Science, 318: 1920-1922 (2007).
[cited by applicant]
Hanna et al., “Direct cell reprogramming is a stochastic process amenable to acceleration”, Nature, 462: 595-601 (2009).
[cited by applicant]
Hanna et al., “Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency”, Cell, 133: 250-264 (2008).
[cited by applicant]
Hanna et al., “Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs,” Proc. Natl. Acad. Sci. USA, 107(20):9222-9227 (2010).
[cited by applicant]
Hanna et al., “Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues,” Cell, 143:508-525 (2010).
[cited by applicant]
Hay, “An overview of epithelio-mesenchymal transformation”, Acta Anat. (Basel) 154: 820 (1995).
[cited by applicant]
Hayashi et al., “Dynamic equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and epigenetic states”, Cell Stem Cell, 3(4): 391-401 (2008).
[cited by applicant]
Heo et al., “EGF stimulates proliferation of mouse embryonic stem cells: involvement of Ca2+ influx and p44/42 MAPKs”, Am J Physiol Cell Physiol, 290(1): C123-133 (2006).
[cited by applicant]
Hindie et al., “Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1,” Nat Chem Biol, 5(10): 758-764 (2009).
[cited by applicant]
Hiraki et al., Culturing human IPS cells under non-feeder conditions alters their basic pluripotent status, Biochemical, 4P-0894 (2010) Abstract only.
[cited by applicant]
Ho et al., “Synthetic Protein Transduction Domains: Enhanced Transduction Potential in Vitro and in Vivo”, Cancer Res., 61: 474-477 (2001).
[cited by applicant]
Hochedlinger et al., “Epigenetic reprogramming and induced pluripotency”, Development, 136(4): 509-23 (2009).
[cited by applicant]
Hochedlinger, et al., “Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues”, Cell, 121(3): 465-477 (2005).
[cited by applicant]
Hochedlinger, et al., “Nuclear reprogramming and pluripotency,” Nature, 441: 1061-1067 (2006).
[cited by applicant]
Hong et al., “Suppression of induced pluripotent stem cell generation by the p53—p21 pathway”, Nature, 460: 1132-1135 (2009).
[cited by applicant]
Hou, et al., “VEGI-192, a New Isoform of TNFSF15, Specifically Eliminates Tumor Vascular Endothelial Cells and Suppresses Tumor Growth”, Clinical Cancer Research, 11: 5595-5602 (2005).
[cited by applicant]
Huangfu et al., “Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds”, Nature Biotechnology, 26: 795-797 (2008).
[cited by applicant]
Huangfu et al., “Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2”, Nature Biotechnology, 26(11): 1269-1275 (2008).
[cited by applicant]
Hudecz et al., “Medium-sized peptides as built in carriers for biologically active compounds,” Medicinal Research Reviews, 25(6):679-736 (2005).
[cited by applicant]
Ichida et al., “A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog”, Cell Stem Cell, 5(5): 491-503(2009).
[cited by applicant]
Ieda et al., “Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors”, Cell, 142, 375-86 (2010).
[cited by applicant]
Inman et al., “SB-431542 is a potent and specific inhibitor of transforming growth factor-0 Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALKS, and ALK7”, Molecular Pharmacology, 62(1): 65-74 (20…
[cited by applicant]
Ishizaki et al., “Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases”, Mol. Pharmacol., 57: 976-983 (2000).
[cited by applicant]
Ivashchenko et al., “Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype,” Am. J. Physiol. Heart Circ. Physiol., 305:H913-H922 (2013).
[cited by applicant]
Jean et al., “Pluripotent genes in avian stem cells,” Develop. Growth Differ. 55:41-51 (2013).
[cited by applicant]
Jia et al., “A nonviral minicircle vector for deriving human iPS cells”, Nat Methods, 7(3): 197-199 (2010).
[cited by applicant]
Joliot et al., “alpha-2,8-Polysialic acid is the neuronal surface receptor of antennapedia homeobox peptide”, New Biol., 3(11): 1121-1134 (1991).
[cited by applicant]
Joliot et al., “Antennapedia homeobox peptide regulates neural morphogenesis”, Proc. Natl. Acad. Sci. USA, 88(5): 1864-1868 (1991).
[cited by applicant]
Kaji, et al., “Virus-free induction of pluripotency and subsequent excision of reprogramming factors”, Nature, 458(7239): 771-775 (2009).
[cited by applicant]
Kaminska, et al., “TGF beta signalling and its role in tumour pathogenesis”, Acta Biochimica Polonica, 52(2): 329-337 (2005).
[cited by applicant]
Kanatsu-Shinohara et al., “Generation of pluripotent stem cells from neonatal mouse testis”, Cell, 119(7): 1001-1012 (2004).
[cited by applicant]
Kelly, et al., “Drug insight: Histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid”, Nature Clinical Practice Oncology, 2(3): 150-157 (2005).
[cited by applicant]
Kennedy and Henderson, “Chronic exposure to morphine does not induce dependence at the level of the calcium channel current in human SH-SYSY cells”, Neuroscience, 49(4): 937-44 (1992).
[cited by applicant]
Kim et al. “Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors”, Nature, 454(7204): 646-651 (2008).
[cited by applicant]
Kim et al., “ct4-induced pluripotency in adult neural stem cells”, Cell, 136(3): 411-419, (2009).
[cited by applicant]
Kim et al., “Direct reprogramming of human neural stem cells by OCT4,” Nature, 461(7264):649-653 (2009).
[cited by applicant]
Kim et al., “Direct reprogramming of mouse fibroblasts to neural progenitors”, Proc. Natl. Acad. Sci., USA, 108(9): 7838-7843 (2011).
[cited by applicant]
Kim et al., “Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins,” Cell Stem Cell, 4(6): 472-476 (2009).
[cited by applicant]
Kim et al., Eur J Biochem, “Enzymic properties of recombinant BACE2”, Eur. J. Biochem., 269(22): 5668-5677 (2002).
[cited by applicant]
Kim, et al., “Pharmacokinetics and tissue distribution of 3-45-(6-methylpyridin-2-y1)-4-(quinoxalin-6-y1)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug”, Xenobiotica, 38(3)…
[cited by applicant]
Kitajima, H. et al. (Jun. 11, 2010, e-published May 9, 2010). “Clonal expansion of human pluripotent stem cells on gelatin-coated surface,” Biochem Biophys Res Commun 396(4):933-938.
[cited by applicant]
Klein et al., “The effects of a novel MEK inhibitor PD 184161 on MEK-ERK signaling and growth in human liver cancer”, Neoplasia, 8: 1-8 (2006).
[cited by applicant]
Krippl et al., “Functions of purified ElA protein microinjected into mammalian cells”, Proc. Natl. Acad. Sci. USA, 81(22): 6988-6992 (1984).
[cited by applicant]
Kubicek et al., “Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase,” Molecular Cell, 25(3): 473-481 (2007).
[cited by applicant]
Kurosawa, “Application of Rho-associated protein kinase (ROCK) inhibitor to human pluripotent stem cells,” J. Bioscience Bioengineering, 114(6):577-581 (2012).
[cited by applicant]
Kuzmenkin et al., “Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro”, FASEB J., 23(12): 4168-4180 (2009).
[cited by applicant]
Lafevre, et al., “Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells”, Molecular Cancer Therapeutics, 7(6): 1420-1429 (2008).
[cited by applicant]
Leitch et al., “Naive pluripotency is associated with global DNA hypomethylation,” Nature Structural Molecular Biology, 20(3):311-316 (2013).
[cited by applicant]
Leroux et al., “Neurotrophic activity of the Antennapedia homeodomain depends on its specific DNA-binding properties”, Proc. Natl. Acad. Sci. USA, 90(19): 9120-9124 (1993).
[cited by applicant]
Levenson, “DNA (cytosine-5) methyltransferase inhibitors: a potential therapeutic agent for schizophrenia”, Molecular Pharmacology, 71(3): 635-637 (2007).
[cited by applicant]
Li and Ding, “Generation of novel rat and human pluripotent stem cells by reprogramming and chemical approaches,” Methods in Molecular Biology, 636:293-300 (2010).
[cited by applicant]
Li et al., “Generation of Human-induced Pluripotent Stem Cells in the Absence of Exogenous Sox2”, Stem Cells, 27: 2992-3000 (2009).
[cited by applicant]
Li et al., “MEK/ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal”, Differentiation, 75(4): 299-307 (2007).
[cited by applicant]
Li et al., “Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors,” Cell Stem Cell, 4(1): 16-19 (2009).
[cited by applicant]
Li et al., “Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming,” Trends Pharmacal Sci, 31(1): 36-45 (2010).
[cited by applicant]
Liang et al., “Cyclic adenosine 3',5'-monophosphate-dependent activation of mitogen-activated protein kinase in cumulus cells is essential for germinal vesicle breakdown of porcine cumulus-enclosed oocyte”, Endocrinolog…
[cited by applicant]
Lim et al., “The pluripotency regulator zic3 is a direct activator of the nanog promoter in ESCs,” Stem Cells, 28:1961-1969 (2010).
[cited by applicant]
Lin et al., “A chemical platform for improved induction of human iPSCs”, Nat Methods, 6(11): 805-808 (2009).
[cited by applicant]
Lin et al., “A chemical platform for improved induction of human iPSCs”, Nat Methods, 6:805-808, Supplemental Information, 7 pages (2009).
[cited by applicant]
Lin et al., “Relationships of human immunodeficiency virus protease with eukaryotic aspartic proteases”, Methods Enzymol, 241:195-224 (1994).
[cited by applicant]
Liu, et al., “The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents”, Neuropharmacology, 45(2): 281-292 (2003).
[cited by applicant]
Loh et al., “Generation of induced pluripotent stem cells from human blood,” Blood, 113(22): 5476-5479 (2009).
[cited by applicant]
Lowry et al., “Generation of human induced pluripotent stem cells from dermal fibroblasts”, Proc Natl Acad Sci USA, 105: 2883-2888 (2008).
[cited by applicant]
Lyssiotis et al., “Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4”, PNAS, 106:8912-8917 (2009).
[cited by applicant]
Ma et al., “G9a and Jhdm2a regulate embryonic stem cell fusion-induced reprogramming of adult neural stem cells”, Stem Cells, 26(8):2131-2141 (2008).
[cited by applicant]
Maeda et al., “Endogenous TGF-r3 signaling suppresses maturation of osteoblastic mesencymal cells,” The EMBO Journal, vol. 23, No. 3, Jan. 2004, pp. 552-563.
[cited by applicant]
Maherali et al., “A high-efficiency system for the generation and study of human induced pluripotent stem cells”, Cell Stem Cell, 3(3):340-345 (2008).
[cited by applicant]
Maherali et al., “Guidelines and techniques for the generation of induced pluripotent stem cells”, Cell Stem Cell, 3(6):595-605 (2008).
[cited by applicant]
Maherali et al., “Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling and Widespread Tissue Contribution,” Cell Stem Cell, 1:55-70 (2007).
[cited by applicant]
Maherali et al., “Tgf13 Signal Inhibition Cooperates in the Induction of iPSCs and Replaces Sox2 and cMyc,” Curr. Biology, 19: 1718-1723 (2009).
[cited by applicant]
Mali et al., “Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts”, Stem Cells, 26(8): 1998-2005 (2008).
[cited by applicant]
Manning et al., “AKT/PKB signaling: navigating downstream”, Cell, 129(7): 1261-1274 (2007).
[cited by applicant]
Marson et al., “Wnt signaling promotes reprogramming of somatic cells to pluripotency”, Cell Stem Cell, 3(2): 132-135 (2008).
[cited by applicant]
Martin et al., “Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3”, Nature Immunology, 6(8): 777-784 (2005).
[cited by applicant]
Massague and Chen, “Controlling TGF-beta signaling”, Genes Dev, 14(6): 627-644 (2000).
[cited by applicant]
Massague, J. “TGF-beta signal transduction”, Annu Rev Biochem, 67: 753-791 (1998).
[cited by applicant]
Mattingly et al., “The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD 184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines”, The Journal of Pharma…
[cited by applicant]
Meissner et al., “Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells,” Nature Biotechnology, 25(10): 1177-1181 (2007).
[cited by applicant]
Mikkelsen et al., “Dissecting direct reprogramming through integrative genomic analysis”, Nature, 454(7200) :49-55 (2008).
[cited by applicant]
Miller et al., “Radiation resistance in a doxorubicin-resistant human fibrosarcoma cell line”, Am. J. Clin. Oncol., 15(3): 216-221 (1992).
[cited by applicant]
Mi et al., “Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo”, Mol. Ther., 2(4): 339-347 (2000).
[cited by applicant]
Cited By (1)